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ABSTRACT:
The tumor suppressor protein prostate apoptosis response-4 (PAR-4) is silenced 
in a subset of human cancers and its down-regulation serves as a mechanism for 
cancer cell survival following chemotherapy. PAR-4 re-expression selectively causes 
apoptosis in cancer cells but how its pro-apoptotic functions are controlled and 
executed precisely is currently unknown. We demonstrate here that UV-induced 
apoptosis results in a rapid caspase-dependent PAR-4 cleavage at EEPD131G, a 
sequence that was preferentially recognized by caspase-8. To investigate the effect 
on cell growth for this cleavage event we established stable cell lines that express 
wild-type-PAR-4 or the caspase cleavage resistant mutant PAR-4 D131G under the 
control of a doxycycline-inducible promoter. Induction of the wild-type protein but 
not the mutant interfered with cell proliferation, predominantly through induction of 
apoptosis. We further demonstrate that TNFα-induced apoptosis leads to caspase-8-
dependent PAR-4-cleavage followed by nuclear accumulation of the C-terminal PAR-
4 (132-340) fragment, which then induces apoptosis. Taken together, our results 
indicate that the mechanism by which PAR-4 orchestrates the apoptotic process 
requires cleavage by caspase-8.
 INTRODUCTION
The tumor suppressor protein prostate apoptosis 
response-4 (PAR-4) was initially discovered as a pro-
apoptotic protein in prostate cancer cells undergoing 
apoptosis [1]. Mice lacking Par-4 are prone to enhanced 
tumor development and develop spontaneous tumors 
as well as displaying an increased susceptibility to 
hormone- or chemical-induced cancers [2]. Consistent 
with its role as a tumor suppressor PAR-4 expression is 
silenced in a well-deined subset of cancers including 
renal cancers, neuroblastomas, endometrial carcinomas, 
lung adenocarcinomas, and prostate carcinomas [3-7]. 
In addition, recent indings by Alvarez and coworkers 
document that down-regulation of PAR-4 is necessary 
for tumor cell survival and recurrence of breast cancer 
following targeted therapy in mouse models and in 
patients [8]. Down-regulation of Par-4 by oncogenic 
Ras expression has been shown to require the MEK/
ERK MAPK pathway [9] and consistent with this Par-4 
knockout mice cooperate with oncogenic Kras to induce 
lung adenocarcinomas [6]. Moreover Par-4 was found to 
be an essential regulator of HrasG12V-dependent oncogenic 
growth in a genome-wide RNAi screen [10].
The protein encoded by the PAR-4 gene consists 
of a unique and central SAC (Selective for Apoptosis of 
Cancer cells) domain encompassing a nuclear localization 
sequence (NLS) and a C-terminal leucine zipper domain 
(LZ), which are both 100% conserved in human-, and 
rodent-orthologs [reviewed in 11]. Interaction with 
several proteins, including the atypical PKCs (aPKCs), 
the Wilms’ tumor 1 (WT1) protein and DLK/ZIP kinase 
have been shown to require the leucine zipper domain of 
PAR-4 [12-14]. On the one hand binding of PAR-4 results 
in enzymatic inhibition of the aPKC isoforms PKCζ and 
PKCλ/τ, whereas the interaction with DLK/ZIP kinase and 
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WT1 suggests discrete nuclear functions for PAR-4. The 
central SAC domain has been identiied by serial deletions 
of PAR-4 and has been described to be indispensable for 
the pro-apoptotic activities of PAR-4 [15]. It includes a 
nuclear localization sequence, which promotes nuclear 
entry and over-expression of this core domain alone 
induces apoptosis in a variety of cancer cells but does 
not cause cell death in normal or immortalized cells [15]. 
Moreover transgenic mice that ubiquitously express the 
SAC domain of Par-4 are resistant to the development of 
spontaneous as well as oncogene-induced tumors [16]. 
These data demonstrate an essential role of the PAR-4 
SAC domain for its pro-apoptotic and tumor suppressor 
activities but how these activities are regulated remains 
elusive.
Here we show that UV-induced apoptosis leads to 
a caspase-dependent cleavage of PAR-4 at EEPD131↓G, 
generating two PAR-4 fragments, the irst comprising 
amino acids 1-131 and the second comprising amino acids 
132-340. This cleavage separates the N-terminal part from 
the C-terminal region that contains the NLS, SAC and 
the leucine zipper domains. We further demonstrate that 
TNFα-induced processing of PAR-4 requires caspase-8 
and leads to nuclear translocation of the C-terminal part 
of PAR-4 and thereby induces apoptosis. In summary 
we have demonstrated that PAR-4 is a novel caspase-8 
substrate and provide evidence that PAR-4 cleavage 
downstream of caspase-8 is required for TNFα induced 
apoptosis.
RESULTS
UV-induced apoptosis results in caspase-
dependent PAR-4 cleavage at EEPD131↓G
Previous indings indicated that PAR-4 selectively 
induces apoptosis in cancer cell lines including HeLa cells 
[11]. To further evaluate these indings we treated HeLa 
cells with UV and analyzed the lysates after the indicated 
time points using PARP-1 cleavage as a marker for caspase 
activity (Fig 1A). Within 3 hours of UV treatment eficient 
PARP-1 cleavage was detectable and at the same time a 
PAR-4 fragment of ~17 kDa became visible using a PAR-
4 amino-terminal antibody, suggesting that this protein 
may be cleaved during apoptosis (Fig 1A). To investigate 
whether PAR-4 is hydrolyzed by caspases, HeLa cells 
were treated with UV in the presence or absence of 
Z-VAD-FMK, a potent and pan-speciic caspase inhibitor 
[22]. The pre-incubation with Z-VAD-FMK prevented 
PAR-4 and PARP-1 cleavage in HeLa cells, indicating that 
UV-induced PAR-4 hydrolysis is caspase-dependent (Fig 
1B). To analyze if UV-mediated PAR-4 processing was 
species speciic we overexpressed human and rat PAR-4 in 
Hela cells and treated the cells with UV. Figure 1C shows 
that UV treatment resulted in the generation of a ~17 
kDa N-terminal and a ~28 kDa C-terminal fragment for 
human PAR-4 and a ~15 kDa N-terminal and a ~30 kDa 
C-terminal fragment for rat Par-4, indicating the existence 
of a single cleavage site in both species. We scanned 
the PAR-4 sequence for potential caspase cleavage sites 
on the CASVM server (Server for SVM prediction of 
caspase substrate cleavage sites; www.casbase.org), which 
revealed a potential cleavage site at EEPD131↓G in the 
human protein [23]. To validate this inding we mutated 
Asp131 to Gly, overexpressed PAR-4 and PAR-4 D131G 
in HeLa cells and incubated them for the indicated times 
after UV treatment. Figure 1D demonstrates that a PAR-
4 D131G mutant was resistant to UV-induced processing 
and no cleavage products were generated. These data 
conirmed the existence of a single caspase cleavage site at 
residue EEPD131↓G in human PAR-4. The cleavage site 
separates the N-terminal region from the SAC and leucine 
zipper domains (Fig 1E). This sequence is conserved in 
rat and murine Par-4, albeit slightly shifted towards the 
N-terminus, explaining at least in part the altered mobility 
of cleaved rat Par-4 (Fig 1C and 1E).
Inducible expression of PAR-4 but not PAR-4 
D131G interferes with cell proliferation 
We were next interested if the observed PAR-4 
cleavage exhibits any biological effects. Therefore, we 
generated multiple HeLa Flp-In T-REx cell clones, which 
either express PAR-4 wild-type or PAR-4 D131G from 
the identical locus after the addition of doxycycline (Fig 
2A). Subsequent analysis of the growth characteristics 
of stable cell clones in colony formation assays revealed 
a marked reduction of colony number and also colony 
size upon induced expression of wild-type PAR-4 but 
not PAR-4 D131G (Fig 2B). This was observed with 
four individual clones, and shown here for two clones 
that express either empty vector (#2 and #4), PAR-
4 wild-type (#4 and #6) or PAR-4 D131G (#1 and #2). 
Although the inducible expression of PAR-4 wild-type 
and PAR-4 D131G was comparable (Fig 2A), we noted 
that expression of PAR-4 wild-type led to the generation 
of a caspase cleavage fragment (Fig 2A). This suggested 
that moderate overexpression of PAR-4 was suficient to 
induce caspase activation as observed previously [15]. 
Therefore we compared the capacity of PAR-4 wild-
type and PAR-4 D131G to induce apoptosis. Figure 2C 
illustrates that only expression of PAR-4 wild-type but 
not the caspase cleavage resistant mutant led to increased 
PARP-1 cleavage indicating that caspase processing of 
PAR-4 is necessary to activate its pro-apoptotic properties.
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Figure 2: PAR-4 cleavage leads to inhibition of cell growth. (A) Individual established clones of HeLa Flp-In PAR-4 wild-type 
(WT), PAR-4 D131G and control (empty vector) T-REx cells were treated with 100 ng/ml doxycycline for 72 h. Protein expression was 
analyzed by immunoblotting using the indicated antibodies. N-terminal PAR-4 fragments are indicated. (B) For the colony formation assay, 
200 cells were seeded and grown for 12 days ± doxycycline pior to staining with methylene blue. Two different clones each for PAR-4 
WT, PAR-4 D131G and control cells were analyzed (upper panel). Average values from three independent experiments are displayed. 
Doxycycline treated cells are shown in light grey. Error bars indicate ± SD. P-value was obtained by two-tailed Student’s t-Test, comparing 
doxycycline treated with non-treated cells (lower panel). (C) Hela Flp-In PAR-4 wild-type and PAR-4 D131G cells were grown for 2 days 
± doxycycline. Protein lysates were analyzed with the indicated antibodies. 
Figure 1: PAR-4 is cleaved during UV-induced 
apoptosis at position 131 by caspases. (A) HeLa cells 
were treated with UV (20 mJ x cm-2 at 254 nm) and incubated 
for the indicated time points. Cell lysates were analyzed by 
immunoblotting using antibodies against PAR-4, PARP-1 
and GAPDH. A processed form recognized by an antibody 
that preferentially recognizes the N-terminal part of PAR-4 is 
indicated (cl. PAR-4). (B) HeLa cells were pre-treated with the 
pan-caspase inhibitor Z-VAD-FMK (20 µM) for 30 min, then 
treated as in (A) and incubated for the indicated time points. 
Lysates were analyzed by immunoblotting as above (A). (C) 
HeLa cells were transiently transfected with the indicated 
plasmids (1 µg) and after incubation for 24 h treated with UV 
light as in (A). After further incubation for the indicated time 
points, cell lysates were analyzed by immunoblotting using 
two PAR-4 speciic antibodies that preferentially recognize the 
N-terminal part of the protein (upper panel) or the C-terminal 
part of PAR-4 (middle panel). (D) HeLa cells were transiently 
transfected with plasmids encoding T7-tagged PAR-4 or T7-
tagged PAR-4 D131G (1 µg each). 24 h after transfection and 
treatment with UV for the indicated times, whole cell lysates 
were prepared and analyzed by immunoblotting with T7-speciic 
antibodies recognizing the N-terminus of PAR-4 (upper panel) 
or PAR-4 speciic antibodies that recognize the C-terminal 
part of the protein (middle panel). (E) Schematic overview of 
human PAR-4 protein: the caspase cleavage site at position 131 
adjacent to the SAC domain (selective for apoptosis in cancer 
cells, amino acids 146-203); NLS sequence (nuclear localisation 
signal, amino acids 147-163); LZ motif (leucine zipper, amino 
acids 300-340). The PAR-4 caspase cleavage site is conserved in 
human and rodent orthologs with the exception of a Ser instead 
of Gly at position P1’ in mouse and rat Par-4.
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PAR-4 is a substrate of caspase-8
In order to identify caspases that are capable 
of cleaving PAR-4, immunoprecipitated Flag-tagged 
PAR-4 was subjected to a caspase cleavage assay with 
recombinant caspases 1 to 10 (Fig 3A). Caspase-1, -7 and 
-8 were able to cleave PAR-4 to various degrees in vitro, 
with caspase-8 being the most eficient to hydrolyze full 
length PAR-4 (Fig 3A). The tumor necrosis factor (TNFα) 
receptor family is an established mediator of the extrinsic 
apoptotic pathway and stimulates apoptosis through death-
inducing signaling complex (DISC) formation, which 
includes engagement and activation of caspase-8 [24]. 
To study the role of caspase-8 in PAR-4 processing we 
stimulated HeLa S3 cells for various times with TNFα and 
cycloheximide and found that TNFα-induced signaling led 
to simultaneous PAR-4 and PARP-1 cleavage (Fig 3B). 
Next, we sought to investigate if caspase-8 is required for 
TNFα/CHX induced PAR-4 cleavage. For this purpose, 
we created HeLa S3 cell lines using lentiviral delivery of 
shRNA constructs either expressing two caspase-8-speciic 
shRNAs (sh-caspase-8 #1, #3) or a non-silencing shRNA, 
which serves as a control (sh-control). The expression 
of caspase-8 was strongly reduced in HeLa S3 cells 
transduced with caspase-8 shRNA #1 and #3 as shown in 
Figure 3C (Fig 3C, upper panel). Stimulation with TNFα/
CHX only induced PAR-4 and PARP-1 cleavage in the 
presence of caspase-8 indicating that PAR-4 is downstream 
of caspase-8 (Fig 3C lower panel). Together these indings 
suggest that PAR-4 is a direct target of caspase-8. Recently 
Figure 3: PAR-4 is a substrate of caspase 8. (A) In vitro caspase assay using FLAG-tagged PAR-4 wild-type and recombinant human 
caspases 1-10. The assay was stopped after 30 min by adding sample buffer, and the proteins were subjected to immunoblotting using a PAR-
4 antibody recognizing the C-terminal part of the protein. (B) HeLa S3 cells were stimulated with TNFα (10 ng/ml) in combination with 
CHX (0,5 g/ml) for the indicated time points and with CHX alone for 9 h. Cell lysates were analyzed by immunoblotting with the indicated 
antibodies and PAR-4 cleavage is indicated. (C) Cell lysates from HeLa S3 control (sh-control) or caspase-8-deicient (sh-caspase-8 #1 
and #3) were analyzed by immunoblotting with caspase-8 and GAPDH antibodies (upper panel). HeLa S3 sh-control or sh-caspase-8 #1 
and #3 cells were incubated with TNFα (10 ng/ml) in combination with CHX (0,5 µg/ml) for 3 h. Protein lysates were analyzed by protein 
immunoblotting with antibodies against PAR-4, PARP-1 and GAPDH (lower panel). (D) Caspase-3-deicient MCF-7 cells and MCF-7 cells 
stably expressing caspase-3 were stimulated with TNFα (10 ng/ml) and CHX (0,5 µg/ml) for the indicated time points and protein lysates 
were analyzed by immunoblotting with PAR-4, caspase-3 and GAPDH-speciic antibodies. PAR-4 cleavage products are indicated. (E) 
MCF-7 cells were pre-incubated with 50 µM caspase-8 inhibitor (Z-IETD-FMK) for 30 min and subsequently stimulated with TNFα (10 
ng/ml) and CHX (0,5 µg/ml) for 16 h. Cell lysates were analyzed with the indicated antibodies via immunoblotting and cleavage of PAR-4 
is indicated.
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Chaudhry and coworkers showed that PAR-4 is a substrate 
of caspase-3 and demonstrated that PAR-4 cleavage does 
not occur after cisplatin treatment of caspase-3-deicient 
MCF-7 cells [25]. As our in vitro experiment showed only 
very weak activity of caspase-3 towards PAR-4 (Fig 3A), 
we addressed the role of caspase-3 in our cells. Therefore 
we measured TNFα-induced PAR-4 cleavage in caspase-
3-deicient MCF-7 cells and in caspase-3 reconstituted 
cells (Fig 3D). Stimulation of MCF-7 cells with TNFα 
led to PAR-4 cleavage regardless whether caspase-3 was 
absent or present indicating that TNFα-induced PAR-4 
processing is caspase-3 independent (Fig 3D). Moreover 
pre-treatment of MCF-7 cells with the caspase-8 speciic 
inhibitor Z-IETD-FMK demonstrated that TNFα-induced 
PAR-4 cleavage was caspase-8 dependent (Fig 3E).
Caspase-8-mediated cleavage of PAR-4 leads 
to apoptosis and to nuclear accumulation of the 
C-terminal fragment of PAR-4
To further investigate functional consequences of 
caspase-8-mediated PAR-4 processing, we co-expressed 
wild-type PAR-4 and caspase-8 in HEK 293 cells. Forced 
Figure 4: Caspase-8-mediated PAR-4 cleavage promotes apoptosis through nuclear translocation. (A) HEK 293 cells 
were transiently transfected with plasmids driving expression of PAR-4 wild-type (1 µg), caspase-8 or caspase-3 (50 ng each) for 16 h. 
Protein lysates were analyzed by protein immunoblotting with the indicated antibodies. PAR-4 cleavage was analyzed with antibodies 
recognizing the C-terminal part of the protein. (B) Schematic representation of PAR-4 wild-type, PAR-4 D131G and PAR-4 ∆131 fused 
to eCFP as used for (C). (C) HEK 293 cells were transiently transfected with the plasmids indicated above (B) and after 16 h analyzed 
by confocal microscopy. DIC: differential interference contrast. (D) HEK 293 cells were transiently transfected as above and after 16 h 
incubation stimulated with UV (20 mJ x cm-2 at 254 nm) or TNFα (10 ng/ml) and CHX (0,5 µg/ml). 8 h after stimulation cells were analyzed 
by confocal microscopy. 
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expression of caspase-8 and PAR-4 on there own has been 
shown to trigger apoptosis and therefore we carefully 
titrated the amounts to generate conditions under which 
overexpression of each does not result in the induction 
of apoptosis. Figure 4A demonstrates that expression of 
caspase-8 and PAR-4 on its own does not induce apoptosis 
but co-expression of the two proteins induced PAR-4 and 
PARP-1 cleavage, indicating induction of apoptotic cell 
death. In contrast, co-expression of caspase-3 and PAR-
4 did not result in PAR-4 cleavage or induction of cell 
death (Fig 4A), again underscoring the functional relation 
between caspase-8 and PAR-4. Induction of apoptosis in 
cancer cell lines by expression of the central SAC domain 
of PAR-4 has been shown to require nuclear localization 
(Fig 1E) [15]. To study the localization of the PAR-4 
cleavage product containing the SAC and leucine zipper 
domains, we generated PAR-4 mutants with a C-terminal 
eCFP tag (Fig 4B). Whereas PAR-4 wild-type and PAR-4 
D131G localized to the cytosol as expected, the PAR-4 
mutant lacking the amino-terminal part localized to the 
nucleus (Fig 4C). Moreover, stimulation with TNFα/
CHX or UV resulted in nuclear accumulation of PAR-4 
wild-type, but was prevented in cells expressing PAR-4 
D131G (Fig 4D). These data indicate that caspase-8-
mediated processing of PAR-4 might result in the nuclear 
accumulation of the C-terminal fragment of PAR-4 and 
induction of cell death. 
TNF-induced apoptosis requires caspase-8-
mediated processing of PAR-4 
Next we wanted to analyze whether caspase-8-
mediated PAR-4 cleavage is required to trigger TNFα-
induced cell death in caspase-3-deicient MCF-7 cells. 
Figure 5: PAR-4 is required for TNFα-induced apoptosis. (A) Cell lysates from MCF-7 control (sh-control) or caspase-8 deicient 
(sh-caspase-8 #1 or #3) cells were analyzed by immunoblotting using antibodies against caspase-8 and GAPDH (left panel). MCF-7 control 
and caspase-8 deicient cells were incubated with CHX (0,5 µg/ml) or TNFα (10 ng/ml) in combination with CHX (0,5 µg/ml) for 10 h. Cell 
lysates were analyzed by protein immunoblotting with antibodies against PAR-4, PARP-1 and GAPDH and (right panel). N-terminal PAR-4 
cleavage products are indicated. (B) MCF-7 control (sh-control) or PAR-4 deicient (sh-PAR-4 #2) cells were treated with CHX (0,5 µg/ml) 
alone or TNFα (10 ng/ml) in combination with CHX (0,5 µg/ml). After 10 h of incubation cell lysates were analyzed by immunoblotting 
with antibodies against PAR-4, PARP-1 and GAPDH. N-terminal PAR-4 cleavage products are illustrated. (C) MCF-7 control (sh-control) 
and caspase-8 deicient cells (sh-caspase-8 #3) were stimulated for 10 h with TNFα (10 ng/ml) and CHX (0,5 g/ml), immunostained with a 
C-terminal PAR-4 antibody (red), treated with Hoechst (blue) for nuclear staining and analyzed by confocal microscopy. DIC: differential 
interference contrast.
sh-control
sh-caspase-8 #1
sh-caspase-8 #3
   +      
            +
                     +
caspase-8
GAPDH
kDa
55-
40-
35-
cl. PARP-1
CHX (10 h)
TNFα/CHX 
(10 h)
+                   +                  +
            +                  +                   +
sh-control
sh-caspase-8 #3
kDa
PAR-4
N-terminus
PARP-1
GAPDH
40-
35-
25-
15-
   130-
   100-
40-
35-
cl. PARP-1
CHX (10 h)
TNFα/CHX 
(10 h)
+                   +                    +
           +                   +                  +
sh-control
sh-PAR-4 #2
PAR-4
N-terminus
kDa
40-
PARP-1
GAPDH
35-
25-
15-
35-
40-
100-
130-
A) B)
C)
DIC
sh-control sh-caspase-8 #3
TNFα/CHX (10 h) TNFα/CHX (10 h)
PAR-4 PAR-4 PAR-4 PAR-4
Hoechst Hoechst Hoechst Hoechst
merge merge merge merge
DIC DIC DIC
Oncotarget2994www.impactjournals.com/oncotarget
Therefore we generated caspase-8-deicient MCF-7 cell 
lines and control cell lines using lentiviral delivery as 
described above (for knockdown eficiency see Fig 5A, 
left panel). The cells were then treated with CHX and 
TNFα/CHX and induction of apoptosis was measured 
by PARP-1 cleavage. While sh-control cells underwent 
apoptosis and showed PAR-4 processing after TNFα/CHX 
stimulation, caspase-8-deicient cells failed to do so (Fig 
5A, right panel). CHX treatment alone was not suficient 
to induce PAR-4 processing and apoptosis. To investigate 
if PAR-4 expression was required for the induction of 
apoptosis in response to TNFα/CHX, we compared PAR-
4-deicient with control MCF-7 cells stimulated with 
TNFα/CHX. Apoptosis was induced in sh-control cells 
but was signiicantly inhibited in PAR-4-depleted cells 
(Fig 5B) and similar results were also obtained in HeLa 
S3 cells (data not shown). To expand on these indings 
we analyzed the localization of endogenous PAR-4 after 
TNFα/CHX induced apoptosis with a C-terminal PAR-
4 antibody. Under apoptotic conditions PAR-4 localized 
to the nucleus while this effect was largely inhibited in 
caspase-8-knockdown cells (Fig 5C). These results suggest 
that PAR-4 cleavage is a direct consequence of caspase-8 
activation and is required for nuclear accumulation 
and induction of apoptosis mediated by the C-terminal 
fragment of PAR-4. 
DISCUSSION
PAR-4 is a multi-domain protein and functions 
as a tumor suppressor in a subset of human cancers. 
It contains pro-apoptotic activities but the signaling 
pathways functioning upstream of PAR-4 are ill deined. 
In this study, we found that PAR-4 is cleaved upon UV- 
and TNFα-induced induction of apoptosis at EEPD131↓G 
and this cleavage site was preferentially recognized by 
caspase-8. Furthermore, caspase-8-mediated PAR-4 
cleavage is critical in regulating cell death triggered by 
TNFα, which indicates that PAR-4 functions downstream 
of caspase-8. 
Like many proteases caspases display cleavage-site 
speciicity and share some extent of amino acid speciicity 
adjacent to the site of hydrolysis, providing some degree 
of substrate site selectivity. Caspases have a strict 
requirement for an aspartate in the P
1
 position, with P
1
-P
1
’ 
being the cleavable bond (P
4
-P
3
-P
2
-P
1
-↓-P
1’
). Differences 
in the amino acids in the P
4
, P
3
, P
2
 positions mainly 
determine caspase speciicity [26]. The optimal caspase-8 
cleavage site was determined to require P
4
 (L, V, D, E) 
P
3
 (E) P
2
 (I, T, V) P
1
 (D) P
1
’ (G, S) [27,28]. The PAR-
4 cleavage site EEPD131↓G fulills these requirements 
except for position P
2
. Human and rodent PAR-4 cleavage 
site motifs are conserved except for position P
1
’ (Fig 1E). 
The P
1
’ residue requires small and uncharged amino acids 
(Gly, Ser, Ala) and instead of a Gly at P
1
’ in human PAR-
4, mouse and rat Par-4 contain a Ser, which its with the 
amino acids required for a bona ide caspase-8 substrate. 
The Cys protease caspase-8 initiates apoptotic cell 
death in response to cell surface activation of TNF death 
receptors by undergoing autocleavage and then initiating 
processing of executioner caspases-3 and -7 [29]. Although 
large-scale proteomics in cells have shown that caspases 
cut hundreds of proteins generally at a single site, only a 
few proteins, such as Bid, p28 Bap31, RIP-1, osteopontin 
and CYLD are reported as caspase-8 substrates [30-34]. 
The tumor suppressor protein PAR-4 predominantly 
comprises an intrinsically disordered protein, with ordered 
segments in the C-terminal domains of the protein [35]. 
In this study we demonstrate that caspase-8 cleaves PAR-
4 after Asp 131, thereby separating the unstructured 
N-terminus from the C-terminal part, which includes 
the NLS-containing SAC domain and the leucine zipper. 
Therefore, the C-terminal fragment possesses all the 
domains required for nuclear translocation and induction 
of apoptosis (Fig 1E). Previous studies have shown that 
nuclear entry of the SAC domain is essential for PAR-
4-induced apoptosis [15]. Our own immunoluorescence 
data demonstrate that cleavage of PAR-4 markedly 
enhances nuclear targeting of the C-terminal cleavage 
product but how this shuttling process is regulated is still 
unknown. One possible mechanism is provided by 14-3-
3 proteins, which are phospho-serine/phospho-threonine 
binding proteins. PAR-4 has been shown to associate with 
the mainly cytosolic 14-3-3 sigma isoform [36,37], which 
also interacts and sequesters the transcription factor YAP 
in the cytosol and thereby prevents it from activating p73-
induced apoptosis in the nucleus [38]. It can therefore be 
speculated that caspase-8-activated hydrolysis of PAR-4 
interferes with 14-3-3-mediated cytoplasmic retention 
of PAR-4, thereby inducing nuclear targeting of the 
C-terminal cleavage product.
In a recent study by Chauhdry et al., the authors 
identiied PAR-4 to be a substrate of caspase-3 during 
apoptosis and demonstrated that cisplatin-induced PAR-
4 cleavage is abrogated in caspase-3-deicient MCF-7 
cells [25]. We analyzed the ability of caspase-1 to -10 to 
hydrolyze PAR-4 in vitro. Only caspase-1, -7 and -8 were 
able to eficiently cleave PAR-4, while caspase-3 showed 
only very weak activity. Moreover, only co-expression 
of PAR-4 with caspase-8, but not with caspase-3, led to 
PAR-4 cleavage and induction of apoptosis in HEK 293 
cells. To verify these data we also utilized caspase-3-
deicient MCF-7 breast cancer cells and analyzed PAR-
4 cleavage after stimulation of TNF death receptors. The 
inlammatory response of cells to the pleiotropic cytokine 
TNFα can be switched to apoptosis by the addition of 
protein synthesis inhibitors that shut down the synthesis 
of the endogenous caspase-8 inhibitor c-FLIP leading 
to caspase-8 activation [39]. Our combined results 
demonstrate that TNFα/CHX-induced PAR-4 cleavage 
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in MCF-7 cells requires caspase-8, but is caspase-3 
independent. Together, our data support a critical role for 
caspase-8 in TNFα-induced hydrolysis of PAR-4. 
As PAR-4 functions as a tumor suppressor in a 
subset of human cancers [11] and can be cleaved by 
caspase-8, our indings might aid in explaining some of 
the controversial functions of caspase-8 in tumorigenesis 
[40]. Caspase-8 has been reported to be silenced in 
a subset of human cancers owing to gene deletion, 
mutation or promoter hypermethylation, all resulting in 
a reduced capacity to trigger apoptosis [reviewed in 40]. 
This strongly suggests that caspase-8 possesses tumor 
suppressor functions and indeed caspase-8 deiciency 
facilitates cellular transformation [41]. Thus, we speculate 
that a role of caspase-8 deiciency in tumorigenesis may 
be in part due to its failure to cleave and induce PAR-4 
translocation and activation.  
In summary, our data demonstrate that PAR-4 is a 
novel substrate of the initiator caspase-8 and is cleaved 
during TNFα- and UV-induced apoptosis. Furthermore, 
we provide evidence that regulation of PAR-4 through its 
hydrolysis by caspase-8 during TNFα-induced apoptosis 
is an essential step for the induction of cell death in 
some cancer cells. Therefore, our observations provide 
evidence for a novel mechanism of the regulation of the 
pro-apoptotic properties of the tumor suppressor protein 
PAR-4 and future studies will address which pathways are 
downstream of caspase-8/PAR-4.
MATERIALS AND METHODS
Cell culture and transfections
All cell lines were cultured at 37°C with 5% CO
2
, 
using either Dulbecco’s modiied Eagle’s medium-
Glutamax I (HeLa, HeLa S3 and HEK 293 cells) or 
RPMI 1640 medium (MCF-7 cells) supplemented with 
10% fetal calf serum. Caspase-3 reconstituted MCF-
7 cells were cultured as described before [17]. For the 
selection of stable HeLa Flp-In T-REx cells 5 µg/ml 
blastidicidine and 100 µg/ml hygromycin were added 
to the medium. To achieve stable PAR-4 and caspase-8 
knockdowns the following plasmids from the Thermo 
Scientiic GIPZ lentiviral shRNA library were used: 
caspase-8 (V2LHS_112730 and V2LHS_112733), PAR-4 
(V2LHS_152662) and non-silencing control (RHS4346). 
Lentiviral transduction procedures were carried out 
as described before [18] and 1 µg/ml puromycin was 
added to the medium of lentiviral transduced HeLa 
S3 and 2 µg/ml puromycin to the medium of MCF-7 
cells. Transient transfection was achieved by calcium 
phosphate precipitation (HEK 293 cells) [19], or by 
using Lipofectamine® 2000 (Invitrogen) according to the 
manufacturer’s instructions. Prior to UV (20 mJ x cm-2 at 
254 nm) treatment cells were washed once with PBS. Cells 
were treated with 10 ng/ml human TNFα (Preprotech) 
in combination with 0,5 µg/ml cycloheximide (Sigma). 
Pretreatment with 20 µM pan-caspase inhibitor Z-VAD-
FMK (Calbiochem) or 50 µM caspase-8 inhibitor Z-IETD-
FMK (Santa Cruz) was performed 30 min prior further 
stimulation.
Stable cell lines
HeLa Flp-In T-Rex cells have been described 
previously [19] and were transfected with pcDNA5/
FRT/TO-PAR-4wt or the respective mutant and pOG44 
(Invitrogen). The transfected cells were selected in media 
containing 5 µg/ml blasticidin and 100 µg/ml hygromycin. 
Monoclonal cell lines were established after initial 
selection. Protein expression was induced by treating the 
cells with 100 ng/ml doxycycline for 72 hours.
Plasmids and mutagenesis
The expression construct pcDNA3-T7-PAR-4 
was generated by ampliication of the PAR-4 cDNA and 
subcloned into pcDNA3-T7.  pcDNA3-T7-PAR-4-D131G 
was constructed by site-directed mutagenesis with the 
QuickChange kit (Stratagene) and conirmed by DNA 
sequencing. PcDNA5/FRT/TO-PAR-4wt or D131G were 
constructed using pcDNA5/FRT/TO (Invitrogen) and 
inserts from the respective pcDNA3-T7-PAR-4 vectors. 
pcDNA5/FRT/TO-PAR-4(132-340) was created using 
5´-GTTTAAGCTTATGGGCGTCCCAGAGAAG-3´ 
senseprimer and 
5´-TTTGGATCCCTACCTGGTCAGCTGACC 
-3´ antisense primers. PAR-4(132-340) was then 
subcloned into the HindIII/AgeI sites of pcDNA5/
FRT/TO/ΔN-STAT-CFP vector using sense 
5´-TTTAAGCTTCGATGGGCGTCCCAGAGAAGGG-3´ 
andantisense 
5´-GCTCACCGGTATGATCCTGGTCAGCTGACCC 
AC-3´ primers to generate pcDNA5/FRT/TO-PAR-
4(132-340)-eCFP. To create pcDNA5/FRT/TO-PAR-
4wt-eCFP and pcDNA5/FRT/TO-PAR-4-D131G-
eCFP constructs, PAR-4wt and PAR-4-D131G were 
subcloned into the pcDNA5/FRT/TO-PAR-4(132-
340)-eCFP vector using HindIII/BglII/SnaBI sites. 
PAR-4wt-Flag was subcloned into the HindIII/
BamHI sites of pcDNA5/FRT/TO vector using sense 
5´-TTTAAGCTTCGATGGCGACCGGTGGCTAC-3´ and 
antisense 5´- GAGTGGATCCTCATTTGTCGTCATCGT 
CTTTGTAGTCCCTGGTCGACTCACCCAC-3´ primers. 
pcDNA3-Par-4wt (rat) and pcDNA3-caspase-3wt have 
been described before [20, 17, 21]. pcDNA3-caspase-8wt-
HA was constructed by site-directed mutagenesis using 
pcDNA3-caspase-8-C360A-HA (gift of Guy Salvesen; 
Addgene plasmid #11818)
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Antibodies
PAR-4 was detected via three different polyclonal 
antibodies. The C-terminus of PAR-4 was detected by 
using the anti-PAR-4 antibodies (Cell Signaling, #2328) 
or anti-PAR-4 (Abcam, #49155), while the N-terminal 
part was detected using anti-PAR-4 antibodies (Santa 
Cruz, #1807). Additional antibodies that were used are 
anti-PARP-1/ARTD-1 (Cell Signaling, #9542), anti-
GAPDH 6C5 (Santa Cruz, #32233), anti-HA Y11 (Santa 
Cruz, #805), anti-caspase-3 (Cell Signaling, #9662) and 
anti-T7 (Novagen, #69522). Secondary antibodies used 
were horseradish peroxidase-labeled IgG goat anti-rabbit 
(#P0448) and rabbit anti-mouse (#P0161) from Dako. 
For confocal microscopy secondary goat anti-rabbit 
IgG conjugated with Alexa Fluor® 555 dye (Invitrogen, 
#A31572) was used.
Colony formation assay
2x102 cells expressing pcDNA5/FRT/TO-PAR-
4wt, pcDNA5/FRT/TO-PAR-4-D131G or the vector 
control were seeded in 6 cm dishes in duplicates. 
Protein expression was induced by addition of 100 ng/
ml doxycycline with consecutive medium changes every 
three days. On day 12, the cells were washed once in PBS 
and subsequently stained with 0.2% methylene blue in 
methanol for 30 minutes. After washing, dishes were dried 
and pictured for documentation. 
Caspase assay
Lysates used for immunoprecipitation of proteins 
subjected to in vitro caspase treatment were generated 
in TLB lysis buffer (50 mM Tris/HCl, pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% Triton-X-100 and a protease 
inhibitor cocktail). The lysates were incubated with FLAG 
M2 beads (Sigma) for 3 hours at 4°C, washed and directly 
used in a caspase assay. 0.1 unit/enzyme recombinant 
human caspases (PromoKine) were incubated with PAR-
4 in 30 µl caspase reaction buffer (50 mM HEPES, pH 
7.2, 50 mM NaCl, 0,1% CHAPS, 10 mM EDTA, 2.5% 
glycerol, 5 mM DTT). After incubation for 30 min at 37°C 
fragments were analyzed by immunoblotting.
Indirect immunoluorescence and confocal 
microscopy
Cells were grown on glass coverslips (18 mm) 
in 12 well plates, washed with PBS and ixed with 
4% paraformaldehyde / PBS for 30 min. Cells were 
permeabilized with PBS containing 0,1% Triton-X-100 for 
30 min and blocked in 3% bovine serum albumin (BSA) 
in PBS for 1 h. PAR-4 was stained with PAR-4 speciic 
antibodies (Abcam, 1:100) and visualized with secondary 
Alexa Fluor® 555 conjugated antibodies (1:1000). 
Hoechst was added and coverslips were mounted with 
ImmuMount (Thermo Scientiic). Images were examined 
with a Zeiss LSM 710 confocal microscope with a LDC-
apochromat 40/1.1 water objective. ZEN 2009 software 
(Zeiss) was used for image editing.
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